Captor Therapeutics Spolka Akcyjna Future Growth
Future criteria checks 2/6
Captor Therapeutics Spolka Akcyjna is forecast to grow revenue at 22.3% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Biotechs earnings growth | 30.9% |
Revenue growth rate | 22.3% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 13 Jun 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 78 | N/A | 6 | 20 | 1 |
12/31/2025 | 54 | N/A | -24 | -9 | 1 |
12/31/2024 | 12 | N/A | -52 | -41 | 1 |
3/31/2024 | 16 | -66 | -58 | -55 | N/A |
12/31/2023 | 13 | -71 | -55 | -52 | N/A |
9/30/2023 | 13 | -66 | -40 | -37 | N/A |
6/30/2023 | 11 | -58 | -43 | -41 | N/A |
3/31/2023 | 10 | -39 | -26 | -25 | N/A |
12/31/2022 | 9 | -36 | -24 | -23 | N/A |
9/30/2022 | 5 | -40 | -32 | -26 | N/A |
6/30/2022 | 5 | -41 | -32 | -27 | N/A |
3/31/2022 | 5 | -38 | -29 | -24 | N/A |
12/31/2021 | 4 | -33 | -34 | -28 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 60Q's forecast earnings growth is above the savings rate (0.7%).
Earnings vs Market: Insufficient data to determine if 60Q's earnings are forecast to grow faster than the German market
High Growth Earnings: Insufficient data to determine if 60Q's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 60Q's revenue (22.3% per year) is forecast to grow faster than the German market (5.2% per year).
High Growth Revenue: 60Q's revenue (22.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 60Q's Return on Equity is forecast to be high in 3 years time